What obicetrapib is
Obicetrapib is an oral, once-daily CETP inhibitor. Cholesteryl ester transfer protein (CETP) moves cholesterol between lipoprotein particles in the blood. Blocking it raises HDL ("good") cholesterol and lowers LDL ("bad") cholesterol and apolipoprotein B. Obicetrapib is developed by NewAmsterdam Pharma, with Menarini as its partner in Europe. It is also available in Europe as a fixed-dose combination with ezetimibe, an older cholesterol drug.
A drug class with a difficult history
Obicetrapib cannot be understood without its predecessors. Four earlier CETP inhibitors reached large cardiovascular outcomes trials, and only one produced a benefit:
| Drug | Outcomes trial result | Lesson |
|---|---|---|
| Torcetrapib | Raised HDL by 72% and lowered LDL by 25%, but increased cardiovascular events (hazard ratio 1.25) and deaths (hazard ratio 1.58) | Off-target effects, including higher blood pressure, can outweigh lipid benefits |
| Dalcetrapib | Raised HDL by 31% to 40% with minimal effect on LDL; trial stopped for futility with no reduction in events (hazard ratio 1.04) | Raising HDL alone did not help |
| Evacetrapib | Lowered LDL by 31% and raised HDL by 133%, but showed no reduction in events (hazard ratio 1.01); stopped early for futility | Large HDL increases did not translate into benefit |
| Anacetrapib | Reduced major coronary events by about 9% (rate ratio 0.91) over a median of 4.1 years | A modest benefit, consistent with its effect on non-HDL cholesterol |
Sources: Barter et al., NEJM (2007); Schwartz et al., NEJM (2012); Lincoff et al., NEJM (2017); HPS3/TIMI55–REVEAL, NEJM (2017).
The anacetrapib result is the most informative. Its benefit appeared to track the lowering of non-HDL cholesterol rather than the large rise in HDL. That has shifted the rationale for the class: modern CETP inhibitors such as obicetrapib are positioned primarily as LDL-lowering drugs.
Clinical evidence
BROADWAY
BROADWAY enrolled 2,530 patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia who were already on maximum tolerated lipid-lowering therapy, with a mean baseline LDL cholesterol of 98 mg/dL. Published in the New England Journal of Medicine in 2025:
- LDL cholesterol changed by −29.9% with obicetrapib and +2.7% with placebo at day 84, a difference of −32.6 percentage points.
- The incidence of adverse events appeared similar between groups.
Other Phase 3 trials
The company reports that BROOKLYN, in heterozygous familial hypercholesterolemia, and TANDEM, testing the ezetimibe combination, also supported the EU approval. It cites LDL reductions of up to 40% for monotherapy and about 50% for the combination versus placebo (company-reported). Detailed results for each trial are on ClinicalTrials.gov, linked in the trial table below.
PREVAIL
PREVAIL is the trial that will decide obicetrapib's long-term place. It enrolled 9,541 patients (registry) and measures major adverse cardiovascular events. The company reports that enrollment was completed in April 2024. The registry lists an estimated primary completion of November 2026.
Scientific perspective
Obicetrapib's case rests on two points. First, it lowers LDL cholesterol meaningfully on top of existing therapy, and LDL lowering by many mechanisms has reduced cardiovascular events in past trials. Second, in BROADWAY the incidence of adverse events appeared similar to placebo. Torcetrapib's harms have been linked to effects beyond CETP inhibition, including higher blood pressure, so long-term safety data from PREVAIL will be watched closely.
The open question is whether CETP inhibition delivers the benefit expected from its LDL lowering, or whether something specific to the class blunts it. Anacetrapib's modest result suggests the benefit is real but proportional to the cholesterol change. PREVAIL will test this with a larger LDL effect.
Development perspective
- Europe: approved by the European Commission on September 21, 2026, for adults with primary hypercholesterolemia or mixed dyslipidemia (company-reported).
- United States: openFDA lists no application record. The company's EU approval announcement did not describe U.S. regulatory plans.
- Key catalyst: PREVAIL. A positive result would strengthen the case for broad use and any U.S. filing. A neutral result would resemble evacetrapib and would likely limit the drug to LDL lowering in patients who cannot reach targets otherwise.
- Alzheimer's disease: a 400-participant Phase 2 trial is recruiting. This is an early, exploratory program, and it is tracked separately from the cardiovascular program.
Competitive context
Obicetrapib competes with established LDL-lowering options: statins, ezetimibe, PCSK9-targeting antibodies and siRNA, the oral PCSK9 inhibitor enlicitide (FDA-approved in 2026), and bempedoic acid. Its distinguishing features are oral, once-daily dosing and its potential use in combination. A recruiting Phase 3 trial compares it directly with bempedoic acid (registry).
Development timeline
- Aug 2013TULIP Phase 2 trial of TA-8995 (later named obicetrapib) begins in patients with mild dyslipidemia. Registry
- Dec 15, 2021BROADWAY Phase 3 trial begins. Registry
- Feb 7, 2022PREVAIL cardiovascular outcomes trial begins. Registry
- May 7, 2025BROADWAY results published: LDL cholesterol −29.9% versus +2.7% with placebo at day 84. Peer-reviewed
- Jul 24, 2026EMA's CHMP adopts a positive opinion recommending marketing authorization. Company-reported
- Sep 21, 2026European Commission grants marketing authorization for Ubeslo (obicetrapib) and Evlarco (obicetrapib/ezetimibe). Company-reported
What could change the outlook
- The PREVAIL outcomes result: whether obicetrapib reduces major adverse cardiovascular events. This is the most important pending event for the drug.
- Whether the size of any event reduction is consistent with its LDL-lowering effect, the pattern seen with anacetrapib.
- Any U.S. regulatory submission. The company's EU approval release did not describe U.S. plans.
- Long-term safety in PREVAIL, given the off-target harms that sank torcetrapib.
- Results of the Alzheimer's disease Phase 2 program, an unusual indication for a lipid drug.
Latest company disclosures
Company press releases (SEC filings and PR Newswire) that mention Obicetrapib. Company-reported, not independently verified.
- Pipeline updateCompany-reportedSep 29, 2026
NewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer’s Disease
SPINOZA is studying obicetrapib in adults with biomarker evidence suggestive of preclinical Alzheimer’s disease who do not have noticeable memory or functional symptoms- - The study will evaluate changes in blood-based biomarkers associated with Alzheimer’s disease, including p-tau 217, and additional cognitive and...
- RegulatoryCompany-reportedSep 21, 2026
On September 21, 2026, NewAmsterdam Pharma Company N.V. (the “Company”) along with its partner Menarini Group (“Menarini”) announced that the European Commission (“EC”) has granted marketing authorization for Ubeslo...
® (obicetrapib 10 mg monotherapy) and Evlarco ® (10 mg obicetrapib plus 10 mg ezetimibe fixed-dose combination, or “FDC”) for patients with primary hypercholesterolaemia (heterozygous familial (“HeFH”) and non-familial) or mixed dyslipidaemia, marking the first regulatory approval of obicetrapib worldwide.
- Quarterly reportCompany-reportedAug 5, 2026
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results
“Our quarterly update is headlined by the positive opinion for Europe from CHMP, recommending the granting of a marketing authorization for Ubeslo and Evlarco, intended for the treatment of primary hypercholesterolemia or mixed dyslipidemia.